# EDGAR Filing Document

**Accession Number:** 0001426800
**File Stem:** 0001193125-26-124050
**Filing Date:** 2026-3
**Character Count:** 2587
**Document Hash:** 54fbc5eb927f70b24e45dacb4bf49db6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-124050.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001193125-26-124050

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260325

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASSEMBLY BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001426800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** TWO TOWER PLACE
- **STREET 2:** 7TH FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (833) 409-4583

**MAIL ADDRESS:**
- **STREET 1:** TWO TOWER PLACE
- **STREET 2:** 7TH FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VENTRUS BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 20080211

![img133659365_0.gif](img133659365_0.gif)

March 25, 20236

<u>Via EDGAR</u>

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

**Re: Assembly Biosciences, Inc.**

 **Registration Statement on Form S-3**

 **Filed March 19, 2026**

 **File No. 333-294459**

 **Request for Acceleration of Effective Date**

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, Assembly Biosciences, Inc. (the "Company") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-294459) (the "Registration Statement") to 4:30 p.m. Eastern Time on Friday, March 27, 2026 or as soon thereafter as practicable.

The Company acknowledges that both the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff of the U.S. Securities and Exchange Commission.

Please contact P. Michelle Gasaway of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at +1.213.687.5122 as soon as the Registration Statement has been declared effective or if you have any other questions or concerns regarding this matter.

Regards,

By: <u>/s/ John O. Gunderson</u> 

Name: John O. Gunderson

Title: VP, General Counsel and Corporate Secretary

cc: P. Michelle Gasaway

*Skadden, Arps, Slate, Meagher & Flom LLP*

Jason A. Okazaki

*Assembly Biosciences, Inc.*

Two Tower Place, 7th Floor, South San Francisco, CA 94080

------